Received: from westeu12-emailsignatures-cloud.codetwo.com (13.93.42.39) by AM3PEPF00009BA2.mail.protection.outlook.com (10.167.16.27) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.113.7 via Frontend Transport; Thu, 11 Jun 2026 10:00:05 +0000 Received: from AM3PEPF00009BA2.eurprd04.prod.outlook.com (2603:10a6:20b:21c:cafe::98) by AM9P250CA0002.outlook.office365.com (2603:10a6:20b:21c::7) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.113.13 via Frontend Transport; Thu, 11 Jun 2026 10:00:05 +0000 Received: from GV1PR07CU001.outbound.protection.outlook.com (40.93.214.102) by westeu12-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Thu, 11 Jun 2026 10:00:04 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%4]) with mapi id 15.21.0092.007; Thu, 11 Jun 2026 10:00:00 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by PAVPR02MB9354.eurprd02.prod.outlook.com (2603:10a6:102:30c::20) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.113.11; Thu, 11 Jun 2026 10:00:01 +0000 Received: from DU0PR02MB9678.eurprd02.prod.outlook.com (2603:10a6:10:42e::6) by PA4PR02MB7085.eurprd02.prod.outlook.com with HTTPS; Thu, 11 Jun 2026 10:00:08 +0000 Received: from AM9P250CA0002.EURP250.PROD.OUTLOOK.COM (2603:10a6:20b:21c::7) by DU0PR02MB9678.eurprd02.prod.outlook.com (2603:10a6:10:42e::6) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.113.13; Thu, 11 Jun 2026 10:00:06 +0000 From: "Kommunikatsioon - RA" To: =?iso-8859-1?Q?Keiu_P=F5derson_-_RA?= References: In-Reply-To: Subject: =?iso-8859-1?Q?Ed:_K=FCsimused_seoses_peptiidide_kasvavast_populaarsuse?= =?iso-8859-1?Q?st_=28=D5htuleht=29?= Date: Thu, 11 Jun 2026 13:00:00 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0195_01DCF9A2.6344E570" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQKEIQArzL7NVaqKaD1wNtnL3FFLgwJRzZ01 Authentication-Results: spf=pass (sender IP is 13.93.42.39) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=pass action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|PAVPR02MB9354:EE_|AM3PEPF00009BA2:EE_|DU0PR02MB9678:EE_|PA4PR02MB7085:EE_ X-MS-Office365-Filtering-Correlation-Id: affb4071-1203-468a-97d7-08dec7a03675 X-MS-Exchange-AtpMessageProperties: SA X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|39142699007|31052699007|23010399003|366016|55112099003|8096899003|56012099006|11063799006|18002099003|22082099003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(39142699007)(31052699007)(23010399003)(366016)(55112099003)(8096899003)(56012099006)(11063799006)(18002099003)(22082099003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: UZjv/v7ihrIrdcBMSypBfgN1dI6x5Gt60owdHCzx/qZBMXndIqNGDjZkfY8qIgAt3Z1shTkL0brNOpKHuM6wHlqsPtRMhxNZ9p7Mo81jzv22G38cUYQV6uATe6o5rB/WNNc70Lywp+EpvkuZDXdMGkr4OwL6XvigovfQxgnPrZXy1npQnSlgMrTbg+aoW1KY3ceUjFOcAOyK5ytjo2Ob8TEURzLacl8UcyZgNERPKtdDEf9HWnAIYGjz1o66YoBUi3dx9XvmffVqe319mjOp+JjCC083yXXLD1T6GJNDPL0fO7/HWj8/beR944NM/naoCCF+dycntjd6vOFM+SIOBQ== X-MS-Exchange-Transport-CrossTenantHeadersStamped: DU0PR02MB9678 X-MS-Exchange-Transport-CrossTenantHeadersStamped: PAVPR02MB9354 X-OrganizationHeadersPreserved: PAVPR02MB9354.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 2778689d-4f4d-4a74-9b03-6a040437acbc.20260611100004@westeu12-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 11 Jun 2026 10:00:05.5560 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: affb4071-1203-468a-97d7-08dec7a03675 X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-SCL: 1 X-CrossPremisesHeadersPromoted: AM3PEPF00009BA2.eurprd04.prod.outlook.com X-CrossPremisesHeadersFiltered: AM3PEPF00009BA2.eurprd04.prod.outlook.com X-MS-Exchange-Transport-CrossTenantHeadersStripped: AM3PEPF00009BA2.eurprd04.prod.outlook.com X-MS-PublicTrafficType: Email X-OriginatorOrg: eegovg01.onmicrosoft.com X-MS-Office365-Filtering-Correlation-Id-Prvs: 5a68272c-0673-47e1-38ff-08dec7a033ac X-Microsoft-Antispam: BCL:0;ARA:13230040|82310400026|39142699007|31052699007|366016|35042699022|23010399003|18002099003|22082099003|55112099003|11063799006|56012099006|8096899003|41050700001; X-Forefront-Antispam-Report: CIP:13.93.42.39;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu12-emailsignatures-cloud.codetwo.com;PTR:westeu12-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(82310400026)(39142699007)(31052699007)(366016)(35042699022)(23010399003)(18002099003)(22082099003)(55112099003)(11063799006)(56012099006)(8096899003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 11 Jun 2026 10:00:05.5225 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: affb4071-1203-468a-97d7-08dec7a03675 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[13.93.42.39];Helo=[westeu12-emailsignatures-cloud.codetwo.com] X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.1523315 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0113.000 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et x-ms-exchange-organization-originalserveripaddress: 10.167.16.27 x-ms-exchange-organization-originalclientipaddress: 87.119.179.29 acceptlanguage: en-GB, ru-RU, en-US msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-06-11T10:00:00.198Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 13.93.42.39 as permitted sender) receiver=protection.outlook.com; client-ip=13.93.42.39; helo=westeu12-emailsignatures-cloud.codetwo.com; pr=C authentication-results-original: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-OlkEid: 00000000FBE30D4A7ED77B47974B2304BB4E84D8070034AD76187591974DBF6C4F76951C873A0100020000000000B3D5AF184A00AB4C8C167C2EB8411B9B0000000012A10000C46458342C455C4382E3199256DEA5BF This is a multipart message in MIME format. ------=_NextPart_000_0195_01DCF9A2.6344E570 Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: 8bit _____ Saatja: Samanta Tsopp Saadetud: teisipäev, 9. juuni 2026 14:11 Adressaat: Kommunikatsioon - RA Teema: Küsimused seoses peptiidide kasvavast populaarsusest (Õhtuleht) Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere! Olen Samanta Tsopp, Õhtulehe suvereporter. Kirjutan lugu peptiidide kasvavast populaarsusest tervise-, ilu- ja fitnessivaldkonnas ning soovin Ravimiameti kommentaari järgmistele küsimustele. Palun võimalusel vastata homme hiljemalt kella 12.00-ks. 1. Kas Ravimiamet on viimastel aastatel täheldanud Eestis peptiidide müügi või kasutamise kasvu? 2. Milliseid peptiide käsitletakse Eestis ravimitena ning milliseid mitte? 3. Kas Eestis on lubatud peptiide vabalt internetist tellida või osta? Millistel juhtudel võib tegemist olla seaduserikkumisega? 4. Kui suur probleem on Ravimiameti hinnangul internetist või välismaistelt veebilehtedelt tellitud peptiidide kasutamine? 5. Kas Ravimiamet on avastanud juhtumeid, kus peptiidipreparaatide koostis ei vastanud pakendil lubatule või sisaldas ohtlikke lisandeid? 6. Millised on peamised terviseriskid, mis kaasnevad kontrollimata päritoluga peptiidide kasutamisega? 7. Kas Ravimiamet on saanud teateid peptiidide kasutamisega seotud kõrvaltoimete või tervisekahjustuste kohta? Kui jah, siis millistest probleemidest on kõige sagedamini teatatud? 8. Kuidas hindab Ravimiamet sotsiaalmeedias levivat peptiidide reklaamimist ja nende kujutamist ohutu alternatiivina steroididele või teistele sooritusvõimet parandavatele ainetele? 9. Mida peaks inimene kindlasti teadma enne peptiidide kasutamist? 10. Kas peptiidide populaarsuse kasv valmistab Ravimiametile muret? Kui jah, siis millistel põhjustel? 11. Kas Ravimiamet näeb vajadust peptiidide müügi või reklaamimise rangemaks reguleerimiseks? Lugupidamisega Samanta Tsopp +372 56297387 ------=_NextPart_000_0195_01DCF9A2.6344E570 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable

Saatja: Samanta Tsopp = <samanta.tsopp@ohtuleht.ee>
Saadetud: teisip=E4ev, 9. juuni 2026 14:11
Adressaat: Kommunikatsioon - RA <press@ravimiamet.ee>
Teema: K=FCsimused seoses peptiidide kasvavast populaarsusest = (=D5htuleht)
 

T=E4helepanu! Tegemist on v=E4lisv=F5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Tere!
Olen Samanta Tsopp, =D5htulehe = suvereporter. Kirjutan lugu peptiidide kasvavast populaarsusest = tervise-, ilu- ja fitnessivaldkonnas ning soovin = Ravimiameti kommentaari j=E4rgmistele k=FCsimustele. Palun = v=F5imalusel vastata homme hiljemalt kella 12.00-ks.
  1. Kas Ravimiamet on viimastel aastatel t=E4heldanud Eestis peptiidide = m=FC=FCgi v=F5i kasutamise kasvu?
  2. Milliseid peptiide k=E4sitletakse Eestis ravimitena ning milliseid = mitte?
  3. Kas Eestis on lubatud peptiide vabalt internetist tellida v=F5i osta? = Millistel juhtudel v=F5ib tegemist olla seaduserikkumisega?
  4. Kui suur probleem on Ravimiameti hinnangul internetist v=F5i = v=E4lismaistelt veebilehtedelt tellitud peptiidide kasutamine?
  5. Kas Ravimiamet on avastanud juhtumeid, kus peptiidipreparaatide koostis = ei vastanud pakendil lubatule v=F5i sisaldas ohtlikke lisandeid?
  6. Millised on peamised terviseriskid, mis kaasnevad kontrollimata = p=E4ritoluga peptiidide kasutamisega?
  7. Kas Ravimiamet on saanud teateid peptiidide kasutamisega seotud = k=F5rvaltoimete v=F5i tervisekahjustuste kohta? Kui jah, siis millistest = probleemidest on k=F5ige sagedamini teatatud?
  8. Kuidas hindab Ravimiamet sotsiaalmeedias levivat peptiidide reklaamimist = ja nende kujutamist ohutu alternatiivina steroididele v=F5i teistele = sooritusv=F5imet parandavatele ainetele?
  9. Mida peaks inimene kindlasti teadma enne = peptiidide kasutamist?
  10. Kas peptiidide populaarsuse kasv valmistab Ravimiametile muret? Kui jah, = siis millistel p=F5hjustel?
  11. Kas Ravimiamet n=E4eb vajadust peptiidide m=FC=FCgi v=F5i reklaamimise = rangemaks reguleerimiseks?
Lugupidamisega 
Samanta Tsopp
+372 56297387


------=_NextPart_000_0195_01DCF9A2.6344E570--